Data For Gilead’s Rising Hep C Star Sofosbuvir Support Initial Filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead reported results from three Phase III trials in February, with data strong enough to support U.S. and European filing for sofosbuvir, the nucleoside it plans eventually to make the foundation of a fixed-dose pill available by 2015.